drugset
drugset / Trial / NCT06448962

Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022

NCT06448962 ↗

Phase 3 Completed 109 enrolled Addpharma Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022

Timeline

Start
2020-10-22
Primary completion
2021-11-22
Completion
2021-11-22

Drugs

EvaluationDrugModalityDoseRoute
Subject AD-2021 Unknown — Oral
Subject AD-2022 Unknown — Oral

Indications

essential hypertension hyperlipoproteinemia